Media stories about Psychemedics (NASDAQ:PMD) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Psychemedics earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.1651492656648 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Psychemedics stock traded down $0.29 during trading hours on Friday, reaching $21.43. The company’s stock had a trading volume of 15,045 shares, compared to its average volume of 8,051. Psychemedics has a one year low of $15.99 and a one year high of $22.88. The firm has a market capitalization of $119.62 million, a price-to-earnings ratio of 23.87 and a beta of 0.68. The company has a current ratio of 2.83, a quick ratio of 2.83 and a debt-to-equity ratio of 0.11.
Psychemedics (NASDAQ:PMD) last released its quarterly earnings results on Tuesday, July 24th. The company reported $0.21 earnings per share for the quarter. Psychemedics had a net margin of 14.79% and a return on equity of 27.53%. The company had revenue of $10.79 million for the quarter.
In other news, VP Neil Lerner sold 4,892 shares of Psychemedics stock in a transaction dated Tuesday, May 22nd. The shares were sold at an average price of $20.08, for a total value of $98,231.36. Following the completion of the transaction, the vice president now owns 24,156 shares in the company, valued at $485,052.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is owned by company insiders.
Psychemedics Company Profile
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.
Read More: What does EPS mean?
Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.